Xcout Intel
Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Subscribe to see Maze Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Maze Therapeutics, Inc. at a glance
Maze Therapeutics, Inc. is a drug discovery company headquartered in South San Francisco, United States. It is publicly listed (MAZE) with a market capitalisation of $1.5B. Xcout tracks 38 named people at Maze Therapeutics, Inc., including Jason V. Coloma (Chief Executive Officer & Director). Xcout recorded 29 job postings from Maze Therapeutics, Inc. in the last 90 days.
Maze Therapeutics, Inc. leadership
- Jason V. ColomaChief Executive Officer & Director
- Jason ColomaChief Executive Officer
- Harold S. BernsteinPresident of Research & Development and Chief Medical Officer
- Harold BernsteinPresident, Research and Development and Chief Medical Officer
- Misbah TahirCFO & Principal Accounting Officer
- Atul DandekarChief Strategy & Business Officer
32 more named people on record for Maze Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Maze Therapeutics, Inc.
Xcout recorded 29 job postings from Maze Therapeutics, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Maze Therapeutics, Inc.'s hiring signals →
Maze Therapeutics, Inc. competitors
A few of Maze Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Glycomine, Inc. is a biotherapeutics company focused on developing replacement therapies and treatments for serious rare genetic diseases, operating out of major life science hubs in San Francisco and Boston.
Ochre Bio is a biotechnology company developing precision medicines for chronic liver diseases. It uses data from human donor livers, computational biology, and experimental models to identify and validate therapeutic targets for pharmaceutical and biotechnology development.
Alebund Pharmaceuticals is a biopharmaceutical company founded in early 2018 in Shanghai, China, with operations also in Yangzhou City, focusing on the discovery and development of treatments for kidney disease.
Prazer Therapeutics is a biotechnology company founded in 2019 and headquartered in Seoul, South Korea. The company focuses on developing orally available, brain-penetrating small molecule therapeutics utilizing targeted protein degradation technology for novel drug discovery.
Renibus Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Southlake, Texas, dedicated to transforming outcomes in specialty therapeutics and disease treatments.
Metsera, Inc. is a clinical-stage biopharmaceutical company traded on the NASDAQ under the symbol MTSR, with its headquarters located in New York, New York, focusing on next-generation obesity and metabolic portfolios.
Get Maze Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Maze Therapeutics, Inc. in Xcout Intel
- 38 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access